Atlas Venture Associates XI, L.P.'s Net Worth
$47.5 Million
Who is Atlas Venture Associates XI, L.P.?
Atlas Venture Associates XI, L.P. has an estimated net worth of $47.5 Million. This is based on reported shares across multiple companies, which include Dyne Therapeutics, Inc., Akero Therapeutics, Inc., Ikena Oncology, Inc., Xilio Therapeutics, Inc., Day One Biopharmaceuticals, Inc., Third Harmonic Bio, Inc., and Korro Bio, Inc..
SEC CIK
Atlas Venture Associates XI, L.P.'s CIK is 0001780068
Past Insider Trading and Trends
2021 was Atlas Venture Associates XI, L.P.'s most active year for acquiring shares with 9 total transactions. Atlas Venture Associates XI, L.P.'s most active month to acquire stocks was the month of May. 2021 was Atlas Venture Associates XI, L.P.'s most active year for disposing of shares, totalling 9 transactions. Atlas Venture Associates XI, L.P.'s most active month to dispose stocks was the month of August. 2022 saw Atlas Venture Associates XI, L.P. paying a total of $26,600,021.70 for 9,067,718 shares, this is the most they've acquired in one year. In 2021 Atlas Venture Associates XI, L.P. cashed out on 42,513,152 shares for a total of $385,571.87, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Dyne Therapeutics, Inc. (DYN) Snapshot price: $21.5
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.89% | -807.84K |
$24.32 | -$19,626,902.97 | 12.9M |
Scheduled
|
Feb 26 - Feb 28
| ||
Form 4
| -5.35% | -500.79K |
$22.68 | -$11,339,780.44 | 8.86M |
Scheduled
|
Feb 21 - Feb 23
| ||
Form 4
| -6.96% | -510.15K |
$23.26 | -$11,867,292.26 | 6.82M |
Scheduled
|
Feb 15 - Feb 20
| ||
Form 4
|
∞
| 934.58K |
$10.70 | $10,000,016.70 | 934.58K |
Dec 12
| |||
Form 4
| +361.95% | 7.64M |
—
|
—
| 9.75M |
Sep 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Akero Therapeutics, Inc. (AKRO) Snapshot price: $17.88
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.97M |
$16.00 |
—
| 3.97M |
Jun 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ikena Oncology, Inc. (IKNA) Snapshot price: $1.39
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.89% | 98.72K |
$15.34 | $1,614,428.13 | 2.12M |
Mar 30 - Dec 14
| |||
Form 4
| +2,809.29% | 4.75M |
—
|
—
| 4.92M |
Mar 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.63
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.04% | -1.00K |
$0.64 | -$640.00 | 2.75M |
Feb 8
| |||
Form 4
| -0.15% | -4.24K |
$0.85 | -$3,600.45 | 2.76M |
Jan 11 - Jan 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $15.83
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 766.67K |
$15.00 | $11,500,005.00 | 766.67K |
Jun 17
| |||
Form 4
|
∞
| 9M |
$16.00 | $8,000,000.00 | 9M |
Feb 1 - Jun 1
| |||
| No matching records found | |||||||||